Jcurve Solutions Ltd

JCS

JCurve Solutions Ltd. engages in the business of developing software applications and solutions for corporate and government industries. The company is headquartered in Chatswood, New South Wales. The company went IPO on 2000-12-08. The firm is engaged in the sale, implementation and support of Enterprise Resource Planning (ERP) solutions, which consist of the exclusively licensed small business edition of Oracle NetSuite, JCurve ERP (in Australia and New Zealand), and the Oracle NetSuite mid-market and enterprise editions. Its segments include ANZ ERP, Asia ERP, TEMS and Quicta. ANZ ERP segment includes ERP cloud-based Business Management solutions and associated consulting services that are sold to Australian and New Zealand customers. Asia ERP segment includes ERP cloud-based Business Management solutions and associated consulting services, which are sold to Southeast Asian customers. TEMS segment develops and markets Telecommunications Expense Management Solutions (JTEL, Full Circle and Phoneware) that are sold to Australian customers. Quicta segment develops and sells service management and scheduling software.

Pharmaxis Ltd

PXS

Pharmaxis Ltd. is a pharmaceutical research company, which engages in the development and commercialization of healthcare products for fibrotic and inflammatory diseases. The company is headquartered in Frenchs Forest, New South Wales. The company went IPO on 2003-11-10. The firm has a productive drug discovery engine and drug candidates in clinical trials. Its drug candidate, PXS-5505, is an orally taken drug that inhibits the lysyl oxidase family of enzymes. PXS-5505 is used for the treatment of the blood cancer myelofibrosis. PXS-5505 is also being investigated as a potential treatment for other cancers, such as liver and pancreatic cancer. Its other drugs in development include PXS-5382 (LOXL2 inhibitor), PXS-6302 (topical pan LOX inhibitor), PXS-4728 (SSAO inhibitor), PXS-4699 (dual SSAO/MAOB inhibitor) and PXS-5370 (dual SSAO/MPO inhibitor). Its drug candidates developed from the pipeline targets diseases where inflammatory and fibrotic processes play a significant role, which include pulmonary fibrosis, chronic kidney disease, NASH, Parkinson's disease and cardiac fibrosis.

Rex Minerals Limited

RXM

Rex Minerals Ltd. engages in the exploration and development of mineral properties. The firm's projects include Hillside Project and Hog Ranch Project. The Hillside Project is located 165 kilometers (kms) from Adelaide and 12 km south of the Ardrossan township on the Yorke Peninsula, South Australia. The Hillside Project is an iron oxide copper gold (IOCG) deposit, under shallow cover, in the Gawler Craton, which collectively hosts the largest copper producing projects in Australia. The Hillside Project has a resource that contains approximately 1.9 Mt of copper (Cu) and 1.5 million ounces (Moz) of gold (Au) and is one of the most significant projects in Australia. The Hog Ranch Gold Property is located in Washoe County in north-west Nevada, approximately 45 km from the California border and 91 km from the Oregon border. The Hog Ranch Gold Property has a Joint Ore Reserve Committee (JORC) compliant Mineral Resource of approximately 2.2 Moz gold.

Kinatico Ltd

KYP

Kinatico Ltd. engages in the provision of screening and verification services. The company is headquartered in Perth, Western Australia. The company went IPO on 2015-09-08. The Company’s solutions comprise pre-employment screening, verification services and workforce compliance management internationally. The company provides real-time workforce compliance management via its core software-as-a-service RegTech solution Cited. By combining certifications and compliance data with business policy and legislative requirements, Cited enables scalable compliance monitoring spanning pre-employment to real-time requirements related to geo-location, roles and tasks applicable across a range of industries. The company also provides a range of pre-employment checks via its CVCheck solution. This is delivered via its technology platform, which include employment screening and verification offering. Its OnCite is a native mobile application available in iOS and Android, that allows workers to manage their own compliance daily, control their own credentials, and share that information.

Syntara Limited

SNT

Syntara Ltd. is a pharmaceutical research company, which engages in the development and commercialization of healthcare products for fibrotic and inflammatory diseases. The company is headquartered in Frenchs Forest, New South Wales. The company went IPO on 2003-11-10. The firm is targeting extracellular matrix dysfunction with its amine oxidase chemistry and other technologies to develop novel medicines for blood cancers and conditions linked to inflammation and fibrosis. The Company’s lead candidate SNT-5505 is for the bone marrow cancer myelofibrosis which causes a build-up of scar tissue that leads to loss of red and white blood cells and platelets. The firm is also advancing both oral and topical pan-LOX inhibitors in scar prevention and scar modification programs. Its product candidate, SNT-4728, is an inhibitor to treat sleep disorders and slow progression of neurodegenerative diseases like Parkinson’s by reducing neuroinflammation. The Company’s other drug candidates target fibrotic and inflammatory diseases such as kidney fibrosis, NASH, pulmonary fibrosis and cardiac fibrosis.